Melanoma immunotherapy

Historical precedents, recent successes and future prospects

Marieke Ig Raaijmakers, Sima Rozati, Simone M. Goldinger, Daniel S. Widmer, Reinhard Dummer, Mitchell P. Levesque

Research output: Contribution to journalReview article

Abstract

The idea of cancer immunotherapy has been around for more than a century; however, the first immunotherapeutic ipilimumab, an anti-CTLA-4 antibody, has only recently been approved by the US FDA for melanoma. With an increasing understanding of the immune response, it is expected that more therapies will follow. This review aims to provide a general overview of immunotherapy in melanoma. We first explain the development of cancer immunotherapy more than a century ago and the general opinions about it over time. This is followed by a general overview of the immune reaction in order to give insight into the possible targets for therapy. Finally, we will discuss the current therapies for melanoma, their shortcomings and why it is important to develop patient stratification criteria. We conclude with an overview of recent discoveries and possible future therapies.

Original languageEnglish (US)
Pages (from-to)169-182
Number of pages14
JournalImmunotherapy
Volume5
Issue number2
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Immunotherapy
Melanoma
Therapeutics
Neoplasms
Antibodies

Keywords

  • cancer immunotherapy
  • cancer testis antigens
  • Canvaxin™
  • CTLA-4
  • immunotherapy
  • interferon
  • melanoma
  • PD-1
  • T-cell therapy
  • vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Raaijmakers, M. I., Rozati, S., Goldinger, S. M., Widmer, D. S., Dummer, R., & Levesque, M. P. (2013). Melanoma immunotherapy: Historical precedents, recent successes and future prospects. Immunotherapy, 5(2), 169-182. https://doi.org/10.2217/imt.12.162

Melanoma immunotherapy : Historical precedents, recent successes and future prospects. / Raaijmakers, Marieke Ig; Rozati, Sima; Goldinger, Simone M.; Widmer, Daniel S.; Dummer, Reinhard; Levesque, Mitchell P.

In: Immunotherapy, Vol. 5, No. 2, 01.02.2013, p. 169-182.

Research output: Contribution to journalReview article

Raaijmakers, MI, Rozati, S, Goldinger, SM, Widmer, DS, Dummer, R & Levesque, MP 2013, 'Melanoma immunotherapy: Historical precedents, recent successes and future prospects', Immunotherapy, vol. 5, no. 2, pp. 169-182. https://doi.org/10.2217/imt.12.162
Raaijmakers, Marieke Ig ; Rozati, Sima ; Goldinger, Simone M. ; Widmer, Daniel S. ; Dummer, Reinhard ; Levesque, Mitchell P. / Melanoma immunotherapy : Historical precedents, recent successes and future prospects. In: Immunotherapy. 2013 ; Vol. 5, No. 2. pp. 169-182.
@article{55c636e1e29047a8bdf1180f4d721a20,
title = "Melanoma immunotherapy: Historical precedents, recent successes and future prospects",
abstract = "The idea of cancer immunotherapy has been around for more than a century; however, the first immunotherapeutic ipilimumab, an anti-CTLA-4 antibody, has only recently been approved by the US FDA for melanoma. With an increasing understanding of the immune response, it is expected that more therapies will follow. This review aims to provide a general overview of immunotherapy in melanoma. We first explain the development of cancer immunotherapy more than a century ago and the general opinions about it over time. This is followed by a general overview of the immune reaction in order to give insight into the possible targets for therapy. Finally, we will discuss the current therapies for melanoma, their shortcomings and why it is important to develop patient stratification criteria. We conclude with an overview of recent discoveries and possible future therapies.",
keywords = "cancer immunotherapy, cancer testis antigens, Canvaxin™, CTLA-4, immunotherapy, interferon, melanoma, PD-1, T-cell therapy, vaccines",
author = "Raaijmakers, {Marieke Ig} and Sima Rozati and Goldinger, {Simone M.} and Widmer, {Daniel S.} and Reinhard Dummer and Levesque, {Mitchell P.}",
year = "2013",
month = "2",
day = "1",
doi = "10.2217/imt.12.162",
language = "English (US)",
volume = "5",
pages = "169--182",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Melanoma immunotherapy

T2 - Historical precedents, recent successes and future prospects

AU - Raaijmakers, Marieke Ig

AU - Rozati, Sima

AU - Goldinger, Simone M.

AU - Widmer, Daniel S.

AU - Dummer, Reinhard

AU - Levesque, Mitchell P.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - The idea of cancer immunotherapy has been around for more than a century; however, the first immunotherapeutic ipilimumab, an anti-CTLA-4 antibody, has only recently been approved by the US FDA for melanoma. With an increasing understanding of the immune response, it is expected that more therapies will follow. This review aims to provide a general overview of immunotherapy in melanoma. We first explain the development of cancer immunotherapy more than a century ago and the general opinions about it over time. This is followed by a general overview of the immune reaction in order to give insight into the possible targets for therapy. Finally, we will discuss the current therapies for melanoma, their shortcomings and why it is important to develop patient stratification criteria. We conclude with an overview of recent discoveries and possible future therapies.

AB - The idea of cancer immunotherapy has been around for more than a century; however, the first immunotherapeutic ipilimumab, an anti-CTLA-4 antibody, has only recently been approved by the US FDA for melanoma. With an increasing understanding of the immune response, it is expected that more therapies will follow. This review aims to provide a general overview of immunotherapy in melanoma. We first explain the development of cancer immunotherapy more than a century ago and the general opinions about it over time. This is followed by a general overview of the immune reaction in order to give insight into the possible targets for therapy. Finally, we will discuss the current therapies for melanoma, their shortcomings and why it is important to develop patient stratification criteria. We conclude with an overview of recent discoveries and possible future therapies.

KW - cancer immunotherapy

KW - cancer testis antigens

KW - Canvaxin™

KW - CTLA-4

KW - immunotherapy

KW - interferon

KW - melanoma

KW - PD-1

KW - T-cell therapy

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=84874024364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874024364&partnerID=8YFLogxK

U2 - 10.2217/imt.12.162

DO - 10.2217/imt.12.162

M3 - Review article

VL - 5

SP - 169

EP - 182

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 2

ER -